Related Experiment Videos
Oral sumatriptan-associated transmural myocardial infarction
1Division of Neurology, St. Michael's Hospital, Toronto, ON, Canada.
Neurology
|December 1, 1995
Summary
Sumatriptan succinate, a migraine medication, may cause myocardial infarction in healthy individuals. Caution is advised for patients with vascular risk factors or coronary artery disease.
Area of Science:
- Cardiology
- Pharmacology
- Neurology
Background:
- Sumatriptan succinate is a widely prescribed medication for acute migraine treatment.
- Migraine patients may have underlying vascular risk factors.
- Myocardial infarction is a serious cardiovascular event characterized by the death of heart muscle tissue.
Observation:
- A 43-year-old healthy male experienced a transmural myocardial infarction shortly after taking 100 mg of oral sumatriptan succinate for a migraine.
- Coronary arteriography showed only minor irregularities in the left anterior descending artery, with no significant obstructive coronary artery disease identified.
Findings:
- The case suggests a potential association between sumatriptan succinate ingestion and the development of myocardial infarction, even in the absence of significant coronary artery disease.
- The mechanism may involve coronary vasospasm induced by sumatriptan, leading to myocardial ischemia.
Implications:
- Oral sumatriptan should be used with caution in patients with any vascular risk factors.
- Sumatriptan succinate should be avoided in patients with known coronary artery disease or a history of coronary vasospasm.
- Further research is warranted to elucidate the cardiovascular safety profile of triptans in diverse patient populations.